SCHEMBL7974679

SCHEMBL7974679

CO/N=C(\CCn1ccnc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 7/20 0.53
DRD2 P14416 3/20 0.53
SIGMAR1 Q99720 2/20 0.43
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SLC6A4 P31645 2/20 0.41
PGR P06401 1/20 0.40
CHRM2 P08172 1/20 0.40
CYP3A4 P08684 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
AR P10275 1/20 0.40
CYP2D6 P10635 1/20 0.40
CHRM1 P11229 1/20 0.40
CYP2C9 P11712 1/20 0.40
ADRB3 P13945 1/20 0.40
IDO1 P14902 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2430518 1.00 DRD4 (0.53) DRD4DRD2SIGMAR1ALOX15HSD17B10
SCHEMBL2434454 0.93 DRD4 (0.49) DRD4DRD2SIGMAR1ALOX15HSD17B10
SCHEMBL7977340 0.93 DRD4 (0.49) DRD4DRD2SIGMAR1ALOX15HSD17B10
SCHEMBL2434453 0.93 DRD4 (0.49) DRD4DRD2SIGMAR1ALOX15HSD17B10
SCHEMBL2430520 0.79 DRD4 (0.51) DRD4DRD2SLC6A4
SCHEMBL12293234 0.79 DRD4 (0.51) DRD4DRD2SLC6A4
SCHEMBL6950168 0.78 SLC6A4 (0.60) SIGMAR1ALOX15HSD17B10SLC6A4TBXA2R
SCHEMBL15286596 0.78 TBXA2R (0.47) SLC6A4PGRCHRM2CYP3A4HTR1A
SCHEMBL15286597 0.78 TBXA2R (0.47) SLC6A4PGRCHRM2CYP3A4HTR1A
SCHEMBL12327095 0.77 ALOX15 (0.47) SIGMAR1ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230428-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2011-09-22 US disclosed
US-20110230428-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2011-09-22 US disclosed
WO-2010011302-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI, INC. (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230428-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF KMO, KYNU, MAOA DRD4 3036/4885DRD2 2185/4885SIGMAR1 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.